Scientific Reports (Nov 2021)

Expression of L-type amino acid transporter 1 is a poor prognostic factor for Non-Hodgkin’s lymphoma

  • Narangerel Jigjidkhorloo,
  • Kohsuke Kanekura,
  • Jun Matsubayashi,
  • Daigo Akahane,
  • Koji Fujita,
  • Keiki Oikawa,
  • Atsushi Kurata,
  • Masakatsu Takanashi,
  • Hitoshi Endou,
  • Toshitaka Nagao,
  • Akihiko Gotoh,
  • Oyundelger Norov,
  • Masahiko Kuroda

DOI
https://doi.org/10.1038/s41598-021-00811-8
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 15

Abstract

Read online

Abstract L-type neutral amino acid transporter 1 (LAT1) is a heterodimeric membrane transport protein involved in neutral amino acid transport. LAT1 is highly expressed in various malignant solid tumors and plays an essential role in cell proliferation. However, its role in malignant lymphoma remains unknown. Here, we evaluated LAT1 expression level in tissues from 138 patients with Non-Hodgkin lymphoma (NHL). Overexpression of LAT1 was confirmed in all types of NHL and we found that there is a significant correlation between the level of LAT1 expression and lymphoma grade. The LAT1 expression was higher in aggressive types of lymphomas when compared with static types of lymphomas, suggesting that active tumor proliferation requires nutrient uptake via LAT1. The expression level of LAT1 was inversely correlated with patients’ survival span. Furthermore, pharmacological inhibition of LAT1 by a specific inhibitor JPH203 inhibits lymphoma cell growth. In conclusion, our study demonstrated that LAT1 expression can be used as a prognostic marker for patients with NHL and targeting LAT1 by JPH203 can be a novel therapeutic modality for NHL.